Tepezza Amgen Australia Pty Ltd
Product name
Tepezza
Sponsor
Accepted date
Apr-2024
Active ingredients
teprotumumab
Proposed indication
For the treatment of Thyroid Eye Disease (TED).
Application type
A (new medicine)
Publication date
Apr-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.